Journal
FASEB JOURNAL
Volume 35, Issue 1, Pages -Publisher
WILEY
DOI: 10.1096/fj.202000300R
Keywords
angiotensin II type 1 receptor; immunotherapy; insulin resistance; leptin receptor; skeletal muscle
Categories
Funding
- National Natural Science Foundation of China (NSFC) [81974106, 91439207, 81670461]
Ask authors/readers for more resources
The study demonstrated that ATRQ beta-001 vaccine and McAb-ATR were effective in improving whole-body insulin resistance by modulating glucose metabolism in skeletal muscle. The vaccine and antibody interact with the leptin receptor, affecting insulin signaling and ultimately leading to the therapeutic effect on insulin resistance.
The angiotensin II type 1 receptor (AT1R) signaling pathway is reported to modulate glucose metabolism. Targeting AT1R, our group invented ATRQ beta-001 vaccine, a novel immunotherapeutic strategy to block the activation of AT1R. Here, we evaluated the therapeutic efficacy of ATRQ beta-001 vaccine in insulin resistance, and investigated the mechanism. Our results showed that ATRQ beta-001 vaccine and specific monoclonal antibody against epitope ATR-001 (McAb-ATR) decreased fasting serum insulin concentration and improved glucose and insulin tolerance in ob/ob mice. These beneficial effects were verified in high-fat diet-induced obese mice. McAb-ATR activated insulin signaling in skeletal muscle and insulin-resistant C2C12 myotubes without affecting liver or white adipose tissue of ob/ob mice. Mechanistically, the favorable impact of McAb-ATR on insulin resistance was abolished in db/db mice and in C2C12 myotubes with leptin receptor knockdown. AT1R knockdown also eradicated the effects of McAb-ATR in C2C12 myotubes. Furthermore, McAb-ATR treatment was able to activate the leptin receptor-mediated JAK2/STAT3 signaling in skeletal muscle of ob/ob mice and C2C12 myotubes. Additionally, angiotensin II downregulated the leptin signaling in skeletal muscle of ob/ob and diet-induced obese mice. We demonstrated that ATRQ beta-001 vaccine and McAb-ATR improved whole-body insulin resistance and regulated glucose metabolism in skeletal muscle in a leptin receptor-dependent manner. Our data suggest that immunotherapy targeting AT1R is a novel strategy for treating insulin resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available